About Aaron Missere
Aaron Missere is the CEO and founder of financial media company Departures Capital Inc. He is an avid and experienced investor, with a primary focus on the cannabis industry. In addition to being a featured contributor to StockNews.com and ETFDailyNews.com, he is an author for SmarterAnalyst.com. Aaron also currently hosts a weekly show on YouTube that recaps and explains the movement in the stock market, with a heavy emphasis on marijuana stocks.
Recent Articles By Aaron Missere
Aurora Cannabis: Buy, Sell, or Hold?
Aurora Cannabis (ACB) may be popular with millennials, but that doesn't mean it is a great stock. The company has had its share of trouble over the last couple years, but shot up over 28% yesterday. Is the stock a buy now? Read more to find out.
Will Innovative Industrial Properties Continue to Move Higher?
After reporting strong earnings, Innovative Industrial Properties (IIPR) announced more positive news. Can this drive the stock's price higher? Read more to find out.
Is Aphria the Top Canadian Cannabis Stock?
As many cannabis companies have struggled this year, there appears to be one company that is rising above the pack, Aphria (APHA). This Canadian cannabis producer has a solid history of profitability, but is it the top cannabis stock to buy right now? Read more to find out.
Is Innovative Industrial Properties a Buy After Earnings?
Innovative Industrial Properties (IIPR) reported its latest financial results this week and they were spectacular. Learn what this means for the company and if you should consider buying the stock.
Why Shares of GW Pharmaceuticals are a Buy for 2021
Cannabis investors got come good news this week as GW Pharmaceuticals (GWPH) reported better than expected results. Learn what drove these results and what they mean for the company going forward.
After Aurora Cannabis’ Announcement This Week, is the Stock a Buy?
Aurora Cannabis (ACB) recently announced it will need more money to finance operations and an analyst changed his tune on the stock. Does this provide a buying opportunity? Read more to get Aaron Missere's thoughts.
Should Investors Buy Cronos Group Ahead of Earnings Next Week?
The cannabis industry has seen its share of setbacks the past few months, and this earnings season has been the same. Will Cronos Group (CRON) be different? Read more to find out.
Should You Buy GW Pharmaceuticals Before They Report Earnings?
GW Pharmaceuticals (GWPH) has been trending lower since its last earnings report, but the stock's price doesn't reflect its revenue potential. Read more to learn if you should purchase the stock ahead of its upcoming earnings report.
Aphria: Should Cannabis Investors ‘Buy the Dip’?
Aphria (APHA) reported earnings last week and missed analyst expectations. This resulted in a strong drop in price, but Aaron thinks investors might not be seeing the whole picture. Read more to get his current thoughts on the company.